Purgo Pipeline
Purgo Scientific is primarily dedicated to addressing unmet needs within orthopedic applications, serving both civilian and defense sectors. In addition, the Purgo team is actively exploring opportunities for the pouch in other areas, including pain management, oncology, and beyond.

Surgical Site Infection
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI
Surgical Site Infection
By the Numbers in the U.S.
Surgical Site Infections Cost the U.S. Healthcare System
$10 BILLION ANNUALLY
And Impact Over 300,000 Patients a Year
#1
Cause of Healthcare Acquired Infections
9,000
Number of U.S. Patients that Die From SSI Annually
#1
Cause of Readmissions After Surgery
9.7
Average Number of Days in Hospital Due to SSI

What are Planktonic Bacteria?
- Individual bacteria.
- Float in a liquid medium like blood.
- Metabolically active.
- More susceptible to antibiotics.
- Readily controlled by host immune cells.

What are Bacterial Biofilms?
- Communities of bacteria.
- Primarily attach to solid surfaces.
- Metabolically inactive.
- Less susceptible to antibiotics.
- Can cause recurring infections.

What are Planktonic Bacteria?
- Individual bacteria.
- Float in a liquid medium like blood.
- Metabolically active.
- More susceptible to antibiotics.
- Readily controlled by host immune cells.

What are Bacterial Biofilms?
- Communities of bacteria.
- Primarily attach to solid surfaces.
- Metabolically inactive.
- Less susceptible to antibiotics.
- Can cause recurring infections.
The Solution

The Right Therapy
Purgo Pouch will deliver an effective tobramycin dose to kill biofilms.

The Right Place
Purgo Pouch targets infection by delivering tobramycin locally in the surgical wound site.

The Right Duration
Purgo Pouch sustains tobramycin delivery for up to 30 days, offering unparallelled versatility.
Kirt Kimball, MD
Purgo Pouch is a breakthrough medical device that will deliver controlled local antibiotics. The promise of controlled local drug delivery without systemic side effects and toxicity is transformative for the treatment and prevention of deep infection. I look forward to using it in my practice.
International College of Surgeons
“Surgical site infection is disastrous in orthopedic practice as it is difficult to rid the bone and joint of the infection.” Prevalence of Surgical Site Infection in Orthopedic Surgery: A 5-year Analysis – June 2014, International Surgery – Official Journal of the International College of Surgeons
Adam Hadhazy
“When encased in biofilms in the human body, bacteria are a thousand times less susceptible to antibiotics."
Edmiston C.E., McBain A.J., Roberts C., Leaper
"The global impact of surgical site infections is monumental and as many as 80% of these infections may involve a microbial biofilm.” Edmiston C.E., McBain A.J., Roberts C., Leaper D. (2015) Clinical and Microbiological Aspects of Biofilm-Associated Surgical Site Infections. In: Donelli G. (eds) Biofilm-based Healthcare-associated Infections. Advances in Experimental Medicine and Biology, vol 830. Springer, Cham. doi.org/10.1007/978-3-319-11038-
David L. Rotherberg, MD
The Purgo Pouch stands as a groundbreaking tool in localized antibiotic delivery, addressing deep infection treatment, prevention, and advancing the current surgical infection management. This level of control over drug delivery is a game-changer, and I am excited to see its impact in my clinical work.
Jeremy Shaw, MD
The Purgo Pouch is a breakthrough medical device that will deliver controlled local antibiotics. The promise of controlled local drug delivery without systemic side effects and toxicity is tranformative for the treatment and prevention of deep infection. I look forward to using it in my practice.
Purgo Pouch Is Superior To Current Clinical Approaches
SSI Treatment Options
Purgo Pouch Sustained Delivery Device*
Effective Planktonic Bacterial Control

Flexibility to Change Antibiotics

Continuous Daily Therapy

Effective Biofilm Eradication

Oral Antibiotic Administration
Effective Planktonic Bacteria Control

Flexibility to Change Antibiotics

Continuous Daily Therapy

Effective Biofilm Eradication

IV Antibiotic Administration
Effective Planktonic Bacteria Control

Flexibility to Change Antibiotics

Continuous Daily Therapy

Effective Biofilm Eradication

Antibiotic-Impregnated Beads
Effective Planktonic Bacteria Control

Flexibility to Change Antibiotics

Continuous Daily Therapy

Effective Biofilm Eradication

Local Antibiotic Powder or Lavage Application
Effective Planktonic Bacteria Control

Flexibility to Change Antibiotics

Continuous Daily Therapy

Effective Biofilm Eradication

*As shown in preclinical studies
Purgo Use Case Pathway
Product/Platform
Discovery
Pre-clinical
Phase 1
Orthopedic surgical site infection – treatment
Manage surgical site infections that affect bone such as in open fractures

Orthopedic surgical site infection – prophylaxis
Prevent surgical site infections from developing in, for example, open fractures
General surgical site infection – treatment
Manage infection present in soft tissue spaces

General surgical site infection – prophylaxis
Prevent infection from developing in soft tissue spaces
Pain management – post-operative
Provide post-surgical pain relief via sustained local anesthetic delivery
Oncology – solid tumors
Target tumors with local delivery of multimodal synergistic small molecule and/or antibody combinations (reduced systemic toxicity)
Bone growth and fracture healing – expedite
Locally deliver bone growth agents (bone morphogenetic protein) expediting fracture healing and bone growth in other applications
Purgo’s Pipeline
Orthopedic surgical site infection – treatment
Manage surgical site infections that affect bone such as in open fractures
Product/Platform
Discovery
Pre-clinical
Phase 1

Orthopedic surgical site infection – prophylaxis
Prevent surgical site infections from developing in, for example, open fractures
Product/Platform
Discovery
Pre-clinical
Phase 1
General surgical site infection – treatment
Manage infection present in soft tissue spaces
Product/Platform
Discovery
Pre-clinical
Phase 1

General surgical site infection – prophylaxis
Prevent infection from developing in soft tissue spaces
Product/Platform
Discovery
Pre-clinical
Phase 1
Pain management – post-operative
Provide post-surgical pain relief via sustained local anesthetic delivery
Product/Platform
Discovery
Pre-clinical
Phase 1
Oncology – solid tumors
Target tumors with local delivery of multimodal synergistic small molecule and/or antibody combinations (reduced systemic toxicity)
Product/Platform
Discovery
Pre-clinical
Phase 1
Bone growth and fracture healing – expedite
Locally deliver bone growth agents (bone morphogenetic protein) expediting fracture healing and bone growth in other applications
Product/Platform
Discovery
Pre-clinical
Phase 1